ES2644723T3 - Identificación de sujetos susceptibles de tratamiento antiangiogénico - Google Patents

Identificación de sujetos susceptibles de tratamiento antiangiogénico Download PDF

Info

Publication number
ES2644723T3
ES2644723T3 ES09800069.8T ES09800069T ES2644723T3 ES 2644723 T3 ES2644723 T3 ES 2644723T3 ES 09800069 T ES09800069 T ES 09800069T ES 2644723 T3 ES2644723 T3 ES 2644723T3
Authority
ES
Spain
Prior art keywords
amount
subject
treatment
cardiac troponin
troponin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09800069.8T
Other languages
English (en)
Spanish (es)
Inventor
Georg Hess
Andrea Horsch
Dietmar Zdunek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40162929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2644723(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2644723T3 publication Critical patent/ES2644723T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES09800069.8T 2008-07-23 2009-07-23 Identificación de sujetos susceptibles de tratamiento antiangiogénico Active ES2644723T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08161014 2008-07-23
EP08161014 2008-07-23
PCT/EP2009/059505 WO2010010153A1 (en) 2008-07-23 2009-07-23 Identification of subjects being susceptible to anti-angiogenesis therapy

Publications (1)

Publication Number Publication Date
ES2644723T3 true ES2644723T3 (es) 2017-11-30

Family

ID=40162929

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09800069.8T Active ES2644723T3 (es) 2008-07-23 2009-07-23 Identificación de sujetos susceptibles de tratamiento antiangiogénico

Country Status (5)

Country Link
US (1) US9983213B2 (https=)
EP (1) EP2321651B1 (https=)
JP (1) JP5606438B2 (https=)
ES (1) ES2644723T3 (https=)
WO (1) WO2010010153A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
BR112013031019A2 (pt) 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
MX2015006955A (es) 2012-12-03 2016-01-25 Almac Diagnostics Ltd Prueba de diagnostico molecular para cancer.
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
BR9207175A (pt) 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
AU774596B2 (en) * 1999-03-15 2004-07-01 Boston Life Sciences, Inc. Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
WO2001061048A2 (en) * 2000-02-17 2001-08-23 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification, assessment, prevention and therapy of human cancers
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
ATE458199T1 (de) 2001-05-04 2010-03-15 Biosite Inc Diagnostische marker der akuten koronaren syndrome und ihre verwendungen
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
CA2567738C (en) * 2004-06-15 2010-12-21 F. Hoffmann-La Roche Ag The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
EP1849009B1 (en) * 2005-01-24 2008-10-29 F. Hoffmann-La Roche AG The use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs.
EP1917024A2 (en) * 2005-08-12 2008-05-07 Regeneron Pharmaceuticals, Inc. Methods of treating diseases with a vegf antagonist
CA2648385C (en) 2006-04-04 2020-09-01 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP1887361A1 (en) * 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
EP1890154B1 (en) 2006-08-16 2012-07-04 F. Hoffmann-La Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
CA2666709A1 (en) 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
WO2008061978A2 (en) * 2006-11-21 2008-05-29 Roche Diagnostics Gmbh Means and methods for optimization of diagnostic and therapeutic approaches in chronic artery disease based on the detection of troponin t and nt-probnp
EP2324358A1 (en) 2008-07-23 2011-05-25 F. Hoffmann-La Roche AG Monitoring anti-angiogenesis therapy

Also Published As

Publication number Publication date
US20110113864A1 (en) 2011-05-19
JP2011528797A (ja) 2011-11-24
EP2321651B1 (en) 2017-08-23
WO2010010153A1 (en) 2010-01-28
JP5606438B2 (ja) 2014-10-15
US9983213B2 (en) 2018-05-29
EP2321651A1 (en) 2011-05-18

Similar Documents

Publication Publication Date Title
US11719710B2 (en) GDF-15 and/or troponin T for predicting kidney failure in heart surgery patients
ES2627337T3 (es) Uso de biomarcadores para controlar una medicación en un sujeto que padece insuficiencia cardíaca
JP6615848B2 (ja) 異常な短縮率（ｆｒａｃｔｉｏｎａｌ ｓｈｏｒｔｅｎｉｎｇ）を持つ患者の同定
ES2644723T3 (es) Identificación de sujetos susceptibles de tratamiento antiangiogénico
ES2390359T3 (es) Troponina cardiaca como marcador de enfermedad arterial coronaria avanzada
US20110113865A1 (en) Using cardiac troponin for monitoring anti-angiogenesis therapy
JP5306218B2 (ja) トロポニンＴおよびＮＴ−ｐｒｏＢＮＰの検出に基づく慢性動脈疾患での診断および治療的アプローチの最適化のための手段および方法
EP2597466A1 (en) Means and methods for proSP-B based diagnosis of alveolar damage in pulmonary hypertension patients
EP2916134B1 (en) Use of Seprase for differential diagnosis of acute dyspnea
EP2383579A1 (en) sFlt-1, cardiac troponins and natriuretic peptides in the recognition of therapy with HER-2 inhibitors
US8440463B2 (en) Predicting renal failure in diabetes patients based on placental growth factor and soluble FLT-1
US20110081671A1 (en) Vascular markers in the remodeling of cardiac injury
US20100086946A1 (en) Plgf, flt1 and endoglin for diagnosing angiogenic status in coronary artery disease
WO2012020045A1 (en) Method for selecting patients with stable coronary artery disease for pci or medical treatment
EP2508890A1 (en) CAIX based diagnosis of heart failure